Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib
复制标题
DOI：
10.1200/jco.2005.01.8234
复制
发表时间：
2005-11-01
影响因子：
45.3
通讯作者：
Greco, A
中科院分区：
文献类型：
--
作者：
Hainsworth, JD;Sosman, JA;Greco, A
目的评价抗血管内皮生长因子（VEGF）抗体联合靶向治疗原发性肝癌的疗效和毒副反应（贝伐单抗）和表皮生长因子受体酪氨酸激酶抑制剂（厄洛替尼），患者和方法63例转移性肾透明细胞癌患者接受贝伐单抗10 mg/kg治疗，kg静脉注射，每2周一次，厄洛替尼150 mg口服，每日一次。治疗8周后对患者进行重新评估;有反应的患者继续治疗，直到他们经历肿瘤进展。结果59例可评估患者中有15例（25%）（95%CI，16%至37%）对治疗有客观反应，另外36例（61%）在治疗8周后病情稳定。只有8名患者（14%）的疾病在该时间点发生进展。中位和1年无进展生存期分别为11个月和43%。中位随访15个月后，中位生存率尚未达到; 18个月时的生存率为60%。治疗一般耐受良好;只有两名患者因毒性（皮疹）而停止治疗。结论贝伐单抗联合厄洛替尼治疗晚期肾癌疗效确切，不良反应少，耐受性好。这两种药物联合使用的功效表明，靶向对肿瘤生长和扩散至关重要的不同途径可能会取得优于任何一种药物单独使用的上级结果。这种和其他靶向药物组合的额外开发是必要的。
Purpose To evaluate the efficacy and toxicity of combined treatment with two targeted agents, an antibody against vascular endothelial growth factor (bevacizumab) and an epidermal growth factor receptor tyrosine kinase inhibitor (erlotinib), in the treatment of patients with metastatic clear-cell renal carcinoma.Patients and Methods Sixty-three patients with metastatic clear-cell renal carcinoma were treated with bevacizumab 10 mg/kg intravenously every 2 weeks and erlotinib 150 mg orally daily. Patients were reevaluated after 8 weeks of treatment; patients who responded continued treatment until they experienced tumor progression.Results Fifteen (25%) of 59 assessable patients (95% CI, 16% to 37%) had objective responses to treatment, and an additional 36 patients (61 %) had stable disease after 8 weeks of treatment. Only eight patients' (14%) disease had progressed at this time point. The median and 1-year progression-free survivals were 11 months and 43%, respectively. After a median follow-up of 15 months, median survival has not been reached; survival at 18 months was 60%. Treatment was generally well tolerated; only two patients discontinued treatment because of toxicity (skin rash). Grade 1/2 skin rash and diarrhea were the most frequent treatment-related toxicities.Conclusion The combination of bevacizumab and erlotinib is an effective and well-tolerated treatment for patients with advanced renal cell carcinoma. The efficacy of these two drugs in combination suggests that targeting of separate pathways critical to tumor growth and dissemination may achieve results superior to either drug as a single agent. Additional development of this and other combinations of targeted agents is warranted.